New payloads drive next-gen antibody–drug conjugates
23 April 2026
Nature Cancer
Peer Review – Mohit Rawat
26 September 2025
Endpoints News
ADC outfit Myricx makes CEO selection
26 September 2025
Fierce Biotech
Myricx Bio appoints Mohit Rawat as CEO as it nears the clinic
23 September 2025
Investors in Healthcare
Reinventing ADC payloads
1 September 2025
FLOT.bio
Myricx Bio wins Cancer Research Horizons Start-Up Achievement Award
13 July 2025
Imperial News
Steen Lisby among Myricx new recruits
8 April 2025
The Pharma Letter
Myricx raises £90M in Europe’s largest series A for NMT inhibitors
10 July 2024
BioWorld
‘Galvanized’ by early data, British biotech Myricx secures $114M series A to take ADCs into clinic
8 July 2024
Fierce Biotech
London based Myricx Bio announced a £90M (~$114M) series A financing today, one of the largest in recent years in the UK region
8 July 2024
BioTech TV
Novo Holdings and Abingworth co-lead £90m financing in Myricx Bio Ltd
8 July 2024
European Biotechnology
Myricx Bio obtains $114m of Series A financing to advance ADC therapeutic pipeline
8 July 2024
Manufacturing Chemist
In pivot to buzzy ADCs, London biotech Myricx raises $114M with Lilly’s support
7 July 2024
Endpoints News
Myricx: ADCs with a lipidation inhibitor payload
13 December 2023
BioCentury
Myricx Bio, WuXi Biologics Enter ADC License Agreement
21 November 2023
Contract Pharma
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
23 October 2023
BioSpace
